As you may know, the GeneSight Psychotropic Report provides information about which medications may require dose adjustments, be less likely to work or have an increased risk of side effects based on your genetic information. In this webinar, we will be discussing how to interpret the GeneSight report, expanding upon the effect of smoking on the metabolism of certain psychotropic medications, and reviewing new data from a real-world study of healthcare utilization for over 20,000 GeneSight tested patients with MDD.

During this webinar, our panel of providers will draw from their clinical expertise to answer questions live and discuss topics such as:
  • Have patient outcomes been assessed when utilizing the GeneSight Psychotropic Report?
  • What does it mean if a medication is in the green bin and why might I see some medications there more frequently than others?
  • How might smoking affect my patients’ GeneSight results?
  • Will my patient’s GeneSight Psychotropic report change over time?

Hear from our Speaker

Ann Groover MD

Carson Felkel MD, FAPA

Bernie Ranchero MD, MS, MBA